AlloVir, Inc. (ALVR): Price-to-Projected Revenue Ratio

AlloVir, Inc. (ALVR) aims to secure a dominant position in the cell therapy niche by outpacing competitors in regulatory matters. The projected P/S ratio on this GURU.Markets chart indicates that the metric remains around . The business relies on external CRO/CMO contractors to reduce costs, while highly qualified management focuses on developing life-saving medicines for immunodeficient patients.

ALVR AlloVir Inc: Price-to-Projected Revenue Ratio in the range 07/04/2022 - 11/13/2026

allovir.com (ALVR) - metric breakdowns and financial figures

- current price and projected stock value:

Stock Price AlloVir|ALVR - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value ALVR|ALVR - Total Company Value

- book value of equity indicators:

Net Assets per Single Share AlloVir|ALVR - Company Book Value|Market Value to Book Value Ratio allovir.com|ALVR - Company Assets

- business debt structure and liquidity details:

- business earnings and investment ratios data:

ALVR - Net Financial Result|Expected Profit AlloVir, Inc.|ALVR - Price to Earnings Multiple|Forward P/E Multiple AlloVir|ALVR - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio ALVR|ALVR - Operating income before deduction of amortization|Net earnings per share (EPS TTM) AlloVir|ALVR - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months allovir.com|ALVR - Earnings per share growth in current year|Expected earnings per share growth for next year AlloVir, Inc.

- sales revenue and business income indicators:

ALVR - Company Revenue|Company Projected Revenue AlloVir|ALVR - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio ALVR

Comprehensive company analysis:ALVR (AlloVir Bio)

AlloVir, Inc. (ALVR) represents a biotech asset in a state of stagnation due to the suspension of several clinical trials. By analyzing the trend of the forward P/S ratio, an investor assesses the company's market value relative to projected revenue, which allows for the identification of business overvaluation or undervaluation during the waiting period for new development strategies through 2026 and filters out short-term market manipulations.

Key competitors

Forward P/S Multiple GILD (Gilead Sciences)|Forward P/S Multiple Cidara Therapeutics Corp CDTX|NVAX - Price-to-Projected Revenue Ratio|CVAC: Price-to-Projected Revenue Ratio|Valneva SE (VALN) - Price-to-Projected Revenue Ratio|VIR (vir.bio) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio SIGA Technologies|Market Cap to Future Revenue Ratio Emergent BioSolutions Inc EBS|Forward Price-to-Revenue Multiple AVIR (Atea Pharmaceuticals Inc)|Price-to-Projected Revenue Ratio IVVD (invivyd.com)|Forward P/S Multiple ENTA (Enanta Pharmaceuticals)|Market Cap to Expected Sales Ratio inovio.com (INO)|HLVX - Price-to-Projected Revenue Ratio|Forward Price to Sales KLRS (Kalaris Therapeutics Inc.)|DYAI (dyadic.com) - Forward Price-to-Revenue Multiple|NanoViricides - Forward Price to Sales|TLPH (Talphera, Inc.) - Forward P/S Multiple|cocrystalpharma.com (COCP) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Traws Pharma, Inc. (TRAW)|dwtx.com - Market Cap to Projected Revenue|Forward P/S Multiple QLGN (Qualigen)|VBIV - Forward Price-to-Revenue Multiple|VIRI: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Vaxart, Inc. VXRT